REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis- Dr. Jonathan Silverberg

Positive results have been released from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in individuals with moderate-to-severe atopic dermatitis.¹

These data, announced on February 10 by Nektar Therapeutics, resulted from the global, phase 2b REZOLVE-AD study, involving 393 individuals with atopic dermatitis. Atopic dermatitis is known to impact around 30 million patients in the US. The US Food and Drug Administration (FDA) granted a Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients aged 12 years and older with atopic dermatitis.²

"These data show that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis," Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at The George Washington University School of Medicine and Health Sciences, said in a statement.¹ "With both monthly and quarterly maintenance dosing, new and sustained responses were observed across the key endpoints of EASI-75, vIGA-0/1 and itch and with a large proportion of patients achieving complete clearance with EASI-100." Click here to read the full article.